This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2022 Feb 17;386(7):696-697.

doi: 10.1056/NEJMe2118465.

The Challenge of Respiratory Syncytial Virus Human Challenge Studies

Larry J Anderson¹, Edward E Walsh¹

Affiliations

Affiliation

¹ From the Department of Pediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, Atlanta (L.J.A.); and the Department of Medicine, University of Rochester School of Medicine, Rochester, NY (E.E.W.).

PMID: 35172061
DOI: 10.1056/NEJMe2118465

Editorial

The Challenge of Respiratory Syncytial Virus Human Challenge Studies

Larry J Anderson et al. N Engl J Med. 2022.

. 2022 Feb 17;386(7):696-697.

doi: 10.1056/NEJMe2118465.

Authors

Larry J Anderson¹, Edward E Walsh¹

Affiliation

¹ From the Department of Pediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, Atlanta (L.J.A.); and the Department of Medicine, University of Rochester School of Medicine, Rochester, NY (E.E.W.).

PMID: 35172061
DOI: 10.1056/NEJMe2118465

No abstract available

PubMed Disclaimer

Comment on

EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge.
Ahmad A, Eze K, Noulin N, Horvathova V, Murray B, Baillet M, Grey L, Mori J, Adda N. Ahmad A, et al. N Engl J Med. 2022 Feb 17;386(7):655-666. doi: 10.1056/NEJMoa2108903. N Engl J Med. 2022. PMID: 35172056 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information